Date prepared: 06\/02\/2023<\/p>\n\n\n\n
Abbreviated name of the issuer: CELON PHARMA S.A.<\/p>\n\n\n\n
Subject: Receipt of a notification regarding a change in the total number of votes in the Company<\/p>\n\n\n\n
Legal basis: Article 70 point 1 of the Act on Public Offering \u2013 acquisition or disposal of a significant block of shares<\/p>\n\n\n\n
Content of the report:<\/p>\n\n\n\n
The Management Board of Celon Pharma S.A. (\u201cCompany\u201d) hereby informs of receiving a notification dated February 2023 from Generali Powszechne Towarzystwo Emerytalne S.A. (\u201eGenerali PTE\u201d) on the funds managed by Generali PTE exceeding the 5% threshold in the total number of votes in Celon Pharma S.A. as a result of Generali PTE\u2019s management acquisition of NNLife Otwarty Fundusz Emerytalny and NNLife Dobrowolny Fundusz Emerytalny on February 1, 2023.<\/p>\n\n\n\n
After the management acquisition, the funds managed by Generali PTE in total held 4,083,585 of the Company\u2019s shares, which constituted an 8.00% share in its share capital and gave the right to exercise 4,083,585 votes at its general meeting, i.e. to 6.18% of the total number of votes in the Company.<\/p>\n\n\n\n
The full contents of the notification constitute an appendix to this report.<\/p>\n","protected":false},"excerpt":{"rendered":"